Wall Street brokerages expect that Denali Therapeutics Inc. (NASDAQ:DNLI) will report sales of $87.98 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Denali Therapeutics’ earnings, with the lowest sales estimate coming in at $4.67 million and the highest estimate coming in at $413.97 million. Denali Therapeutics posted sales of $4.67 million during the same quarter last year, which suggests a positive year-over-year growth rate of 1,783.9%. The company is expected to issue its next quarterly earnings report on Thursday, February 25th.
On average, analysts expect that Denali Therapeutics will report full-year sales of $85.69 million for the current fiscal year, with estimates ranging from $18.80 million to $432.81 million. For the next year, analysts forecast that the company will post sales of $46.77 million, with estimates ranging from $16.00 million to $100.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of $4.19 by ($4.73). Denali Therapeutics had a negative return on equity of 39.19% and a negative net margin of 968.59%. The company had revenue of $9.39 million for the quarter, compared to analyst estimates of $564.69 million.
A number of equities research analysts have issued reports on DNLI shares. JPMorgan Chase & Co. started coverage on shares of Denali Therapeutics in a report on Friday. They set a “positive” rating on the stock. The Goldman Sachs Group boosted their target price on shares of Denali Therapeutics from $61.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, November 10th. BidaskClub cut shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright boosted their target price on shares of Denali Therapeutics from $45.00 to $65.00 and gave the company a “buy” rating in a report on Friday, November 6th. Finally, ValuEngine cut shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 8th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. Denali Therapeutics has a consensus rating of “Buy” and a consensus target price of $51.00.
DNLI stock traded down $3.40 during midday trading on Monday, reaching $76.63. 582,181 shares of the company’s stock traded hands, compared to its average volume of 1,038,732. The company has a 50-day moving average price of $76.43 and a two-hundred day moving average price of $46.23. Denali Therapeutics has a 52 week low of $12.39 and a 52 week high of $93.94. The firm has a market capitalization of $9.19 billion, a PE ratio of -34.67 and a beta of 1.93.
In other Denali Therapeutics news, CEO Ryan J. Watts sold 88,334 shares of the firm’s stock in a transaction dated Monday, January 4th. The shares were sold at an average price of $74.96, for a total value of $6,621,516.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Alexander O. Schuth sold 70,000 shares of the firm’s stock in a transaction dated Monday, January 4th. The stock was sold at an average price of $74.95, for a total transaction of $5,246,500.00. Following the completion of the sale, the chief operating officer now owns 10,686 shares of the company’s stock, valued at $800,915.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 287,958 shares of company stock valued at $21,901,850. 19.30% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC increased its stake in Denali Therapeutics by 325.3% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 87,569 shares of the company’s stock valued at $3,138,000 after buying an additional 66,979 shares during the period. Great West Life Assurance Co. Can increased its position in Denali Therapeutics by 141.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 14,606 shares of the company’s stock worth $87,000 after purchasing an additional 8,562 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Denali Therapeutics by 12.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 471,246 shares of the company’s stock valued at $11,395,000 after acquiring an additional 52,574 shares in the last quarter. Bank of America Corp DE grew its position in Denali Therapeutics by 21.0% in the second quarter. Bank of America Corp DE now owns 33,410 shares of the company’s stock valued at $809,000 after acquiring an additional 5,801 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in Denali Therapeutics in the second quarter valued at approximately $92,000. Institutional investors and hedge funds own 67.91% of the company’s stock.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson’s disease.
Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Denali Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.